BRAIN Biotech Target price 2026 - Analyst rating & recommendation
BRAIN Biotech Classifications & Recommendation
BRAIN Biotech Price Target
| Target Price | €5.10 |
| Price | €2.80 |
| Potential |
82.14%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target BRAIN Biotech 2027 .
The average BRAIN Biotech target price is €5.10.
This is
82.14%
register free of charge
€6.83
143.75%
register free of charge
€5.05
80.36%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend BRAIN Biotech to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BRAIN Biotech stock has an average upside potential 2027 of
82.14%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million € | 7.61 | 50.55 |
| 86.29% | 564.27% | |
| EBITDA Margin | -49.54% | 1.15% |
| 601.40% | 102.32% | |
| Net Margin | -79.63% | -8.08% |
| 297.09% | 89.85% |
4 Analysts have issued a sales forecast BRAIN Biotech 2026 . The average BRAIN Biotech sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an BRAIN Biotech EBITDA forecast 2026. The average BRAIN Biotech EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 BRAIN Biotech Analysts have issued a net profit forecast 2026. The average BRAIN Biotech net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.41 | -0.19 |
| 19.61% | 53.66% | |
| P/E | negative | |
| EV/Sales | 1.20 |
5 Analysts have issued a BRAIN Biotech forecast for earnings per share. The average BRAIN Biotech EPS is
This results in the following potential growth metrics and future valuations:
Current BRAIN Biotech Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| EQUI.TS |
Locked
➜
Locked
|
Locked | Jun 01 2026 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Feb 25 2026 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Feb 24 2026 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Jan 14 2026 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Jun 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Jun 01 2026 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Feb 25 2026 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Feb 24 2026 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Jan 14 2026 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 28 2025 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Jun 18 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
